About Us

In response to perceived threats of biological weapons use by terrorist and rogue nations, the US Department of Defense (DoD) established the Smallpox Vaccination Program in December 2002. During the first several years, the Smallpox Vaccination Program used pre-existing stockpiles of the Dryvax smallpox vaccine that were initially produced in the late 1970s through the early 1980s. First approved by the Food and Drug Administration (FDA) in 1931, the Dryvax vaccine was in use in the US for well over a half-century before the manufacturer, Wyeth Laboratories, ceased production.

On March 1, 2008 a new generation FDA-approved smallpox vaccine, ACAM2000, manufactured by Sanofi Pasteur, officially replaced the Dryvax smallpox vaccine. Similar to Dryvax, ACAM2000 is a live-virus vaccine that uses the vaccinia virus to confer protective immunity against variola virus, the causative agent of smallpox. Another similarity to the Dryvax vaccine is that there is a small potential risk of myopericarditis following receipt of the ACAM2000 smallpox vaccine. Although deemed safe and licensed by the FDA, as with all new drugs and vaccines, post-licensing studies are required to evaluate the long-term safety of ACAM2000.

To this end, the Department of Defense in conjunction with the vaccine manufacturer Sanofi Pasteur, established the ACAM2000 Myopericarditis Registry to monitor any occurrence of myopericarditis following vaccination. The purpose of the Registry is to document the natural history of myopericarditis, look for potential predictive factors for the prognosis of myopericarditis, and to evaluate potential risk for the development and severity of myopericarditis.